Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
- Largest Genomic Study Comparing Gene Expression in Female and Male Patients Presented at ASCO Annual Meeting -
ORLANDO, Fla., May 29 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced results from a study which summarized the gene signatures identified by the O...
Quality Colonoscopy Exam Remains Best Strategy for Detection of Polyps and Cancers According to Experts From the American College of Gastroenterology
BETHESDA, Md., Dec. 16 /PRNewswire-USNewswire/ -- Publication of a Canadian study on colonoscopy's impact on reducing colon cancer deaths suggests a lower impact on mortality than previously reported. Physician experts from the American College of Gastroenterology urge patients and the public to r...
Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
- Results Presented at ASH Annual Meeting-
SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological mali...
SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
FRESNO, Calif., Oct. 29 /PRNewswire/ -- Cypress Systems, Inc., a Fresno
CA based biotechnology company, emphasizes that the SELECT TRIAL results --
that were announced yesterday -- used a form of selenium known as
selenomethionine. The SELECT TRIAL found no effects of either
Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
PHILADELPHIA, May 13 /PRNewswire-USNewswire/ -- In women at increased
risk for breast cancer, adding a screening ultrasound examination to
routine mammography revealed 28 percent more cancers
alone. However, the additional ultrasound exam substantially increased the
rates of f...
Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
- Second research program centered on potential target in inflammatory indications such as rheumatoid arthritis -
NUTLEY, N.J., April 15 /PRNewswire/ -- Roche announced today that it
will acquire Piramed Limited, a privately-owned UK company focusing on
therapeutics targeting PI...
Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
- U.S. Data Highlights Oral Xeloda versus Standard Infusional Chemotherapy in Gastroesophageal and Colorectal Cancers
NUTLEY, N.J., Jan. 24 /PRNewswire/ -- Roche announced today that a
total of 33 abstracts involving its oral chemotherapy Xeloda(R) have been
accepted for presenta...
New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
SYDNEY, April 20 /PRNewswire/ -- Australian medical research company Immune System Therapeutics Ltd (IST) has launched a clinical trial to test its breakthrough treatment for terminal blood cancers.
IST has genetically engineered an antibody drug that binds specifically to a target protein fo...
Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers
DENVER, April 19 /PRNewswire/ -- The search for the cause of an inherited form of a rare, aggressive childhood lung cancer has uncovered important information about how the cancer develops and potentially sheds light on the development of other cancers.
The finding by researchers at Washing...
Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers
TORONTO, Feb. 5 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; PREMF.pk) today announced that its recently completed clinical trial data was presented at the 4th Annual Academic Surgical Congress in Fort Myers, FL. The peer reviewed data was presented by Dr. Anees B. Ch...
New Breast Imaging Technology Targets Hard-to-Detect Cancers
CHICAGO, Dec. 3 /PRNewswire-USNewswire/ -- Breast-specific gamma imaging
(BSGI) is effective in the detection of cancers
not found on mammograms or by
clinical exam, according to a study presented today at the annual meeting of
the Radiological Society of North America (RSNA).
"BSGI can id...
DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers
DETROIT, Sept. 15 /PRNewswire-USNewswire/ -- Researchers at the Barbara
Ann Karmanos Cancer Institute and Wayne State University School of Medicine
have developed a HER2 DNA vaccine that has shown to be effective on drug
resistant tumors in mice. The study was reported in the September 15 issu...
EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
Multi-Center Clinical Trial to be Conducted in Canada
ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- EntreMed, Inc.
(Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer and inflammatory diseases, today
announced the commencem...
Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
Positive Results Prompt Phase 2 Trial of JX-594 in Liver and Head and Neck Cancers
SAN FRANCISCO, Oct. 23 /PRNewswire/ -- Jennerex Biotherapeutics today
presented clinical data from a Phase 1 / 2 trial of JX-594 -- the company's
proprietary targeted lytic and immu...
MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed
with Breast Cancer
PHILADELPHIA, March 28, 2007 /PRNewswire-USNewswire/ -- Magnetic
Resonance Imaging (MRI) scans of women who were diagnosed with
cancer in one breast detected over 90 percent of cancers
other breast that were missed by mammography and clinical breast
exam at initial diagnosis, according to a...
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90
Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory
Breast and Ovarian Cancers at ASCO
Clinical Benefit Shown in 35% of HER2-Positive Metastatic Breast
HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan
Biosciences Incorporated presented data from a Phase 1 clinical
trial showing that alvespimycin, its second-generation Hsp90
inhibitor, demonstrated promi...
Human Genome Sciences Reports Growing Evidence That Its TRAIL
Receptor Antibodies Have Significant Potential in the Treatment of
a Broad Range of Cancers
- Journal of Clinical Oncology publishes first clinical study of
ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- Human
Genome Sciences, Inc. today reported that clinical and preclinical
evidence continues to emerge demonstrating that its TRAIL receptor
antibodies, HGS-ETR1 (map...
Poniard Pharmaceuticals Announces Promising Data From Interim
Safety Analysis of Phase 1 Combination Trials of Picoplatin in
Colorectal and Prostate Cancers
- Company Planning to Initiate Phase 2 Trials in Colorectal Cancer
and in Hormone-Refractory Prostate Cancer in Q307 -
SOUTH SAN FRANCISCO, Calif., June 01, 2007
/PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a
biopharmaceutical company focused on oncology, today announced
Publication Confirms that EpCAM, the Target for Two of Micromet's
Product Candidates, Is Overexpressed on Cancer Stem Cells of
BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet,
Inc. , a biopharmaceutical company focusing on the development of
novel, proprietary antibody-based products for cancer, inflammatory
and autoimmune diseases, announced that a study published recently
in the Proceedings of the Nation...
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
...cord compression. All are serious complications for advanced cancer patients.
Regardless of the type of underlying cancer, the process by which cancers
invade and destroy bones is fundamentally the same. At the center of this destructive process is a protein RANK Ligand that is stimulated by the prese...
First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center
...reatments on three patients with non-melanoma skin cancers
under the direction of James S. Welsh, M.S., M.D.,...so FDA cleared for use in the treatment of surface cancers
or conditions where radiation therapy is indicated... is also cleared for use in the treatment of other cancers
or conditions where radiation therapy is indicated...
July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals
...lay a role in the body's immune function. It's long been thought that diets rich in antioxidants, such as vitamin E, could help lower the risk of some cancers
and heart disease. Recent studies suggest that vitamin E supplements don't provide the same health benefits as dietary sources do and may even by harm...
International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit
...nos Cancer Institute's National Center for Vermiculite and Asbestos-Related cancers
(NCVAC) have discovered a probable reason for the unrelenting chest pain ex... National Center for Vermiculite and Asbestos-Related cancers
(NCVAC at Karmanos)
In response to the United States Environmental...
Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
...ertain cell lines," said Dr. Brad Thompson, President and CEO of Oncolytics. "We are currently using drug combinations against NSCLC and head and neck cancers
in two separate U.S. Phase II studies."
The investigators examined in vitro combination effects of reovirus alone and in combination with cisplatin,...
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
... and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year. In addition, the cancers
of many previously-diagnosed patients remain unresolved, sometimes leading to cystectomy (bladder removal) or death. Approximately 70 percent of bladd...
Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story
...ce in survival based on race for a number of other cancers
-- lung, colon, lymphoma, leukemia, and multiple m... African-American patients with one of these three cancers
faced a significantly higher risk of death than di... the metabolism of chemotherapy drugs or that make cancers
more resistant or more aggressive," she adds.
USC Keck School of Medicine's Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic
...ntal Therapeutics Program. These resources will be used to further the preclinical development of his IL-2 analog therapy for the treatment of certain cancers
that appears to retain the benefits of existing IL-2 therapies without the major side effects that currently limit their application.
Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet
...f these, approximately 15 virus types are known to cause cervical cancer. HPV types 16 and 18 are responsible for approximately 70 percent of cervical cancers
globally, with types 45, 31 and 33 among the next most common cervical cancer-causing HPV strains. Persistent infection with cancer-causing HPV types ...
Gene Findings Unlocking Reasons for Neuroblastoma Risk
...id Maris. "Instead, surprisingly, our genome-wide association studies found that BARD1 is a susceptibility gene for neuroblastoma, and perhaps other cancers
Maris added that researchers are now working to understand the mechanism by which BARD1 gene variants act on developing nervous syste...
Alfacell Provides Shareholder Update
...ccess. I believe we have a unique opportunity to make a noticeable impact in the field of oncology giving those patients debilitated by these dreadful cancers
the opportunity to live meaningful lives while we continue to find better therapies and one day a permanent cure for cancer.
Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients
...ents, 303 were male and 437 female, with a mean age at presentation of 55.7 years (SD = 10.2). The mean BMI was 27.9 kg/m2 (SD = 6.7). The most common cancers
were lung (134, 18.1%), breast (131, 17.7%), colorectal (97, 13.1%), pancreatic (86, 11.6%), prostate (45, 6.1%) and ovarian (39, 5.3%). The mean vita...
UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
...ust and validated manufacturing processes
under GMP. Gamida Cell's flagship product, StemEx, is now being studied as a
therapy for patients with blood cancers
in an international pivotal trial at
leading transplant centers in the U.S., Europe and Israel. StemEx has orphan
drug designation in the U.S. and in ...
Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
... Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers
through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These pro...
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
... stomach discomfort
If you take SIMPONI(TM) or other TNF blockers, your risk for developing lymphoma or other cancers
may increase. You should tell your doctor if you have had or develop lymphoma or other cancers.
Heart failure can occur or get worse in people wh...
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
...). Malignancies reported through week 104 consisted of two basal cell skin cancers
(one patient on SIMPONI 100 mg, one placebo patient). No deaths occurred.
...MPONI(TM) or other TNF blockers, your risk for developing lymphoma or other cancers
may increase. You should tell your doctor if you have had or develop lympho...
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
...ietary percutaneous hepatic perfusion (PHP(TM)) system for the treatment of cancers
of the liver, announced today that it has achieved the seventy-five percent...ients in Phase III and Phase II clinical studies for the treatment of liver cancers
using high doses of melphalan. The Company's intellectual property portfoli...
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
...HL, diffuse large B-cell lymphoma (DLBCL).
Non-Hodgkin's lymphoma and Hodgkin's disease, also known as Hodgkin's lymphoma, refer to a variety of cancers
affecting the immune system, such as DLBCL, mantle cell lymphoma and follicular lymphoma(2). Up to 60% of patients with aggressive types of NHL, inclu...
Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
...-Helw of the Weston Park Hospital, Sheffield UK.
The review focuses on the impressive preclinical anti-tumor activity demonstrated in hematologic cancers
over standard anthracyclines and the rational design modifications to the chemical compound believed to be responsible for enhanced DNA damage and bin...
Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis
...ients who smoked two packs a day had a 58 percent higher risk of their lung cancers
returning or spreading compared with nonsmoking patients.
Smoking inte...atients who smoked more than 61 packs a year had the greatest risk of their cancers
recurring, and their survival times were shortest. They were 41 percent mor...
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
... therapies target
these receptors; for example, tamoxifen for estrogen receptor and trastuzumab
(Herceptin(r)) for HER2. However, 15-20% of all breast cancers
over-expression of all three proteins, thus giving rise to the term "triple-
negative breast cancer" or "TNBC."
TNBC can be an aggressive ...